Headlands Technologies LLC Purchases Shares of 10,064 AtriCure, Inc. $ATRC

Headlands Technologies LLC bought a new position in shares of AtriCure, Inc. (NASDAQ:ATRC) during the 2nd quarter, HoldingsChannel.com reports. The fund bought 10,064 shares of the medical device company’s stock, valued at approximately $282,000.

Other hedge funds also recently modified their holdings of the company. BlackRock Inc. purchased a new position in AtriCure during the 2nd quarter valued at about $125,198,000. Bank of America Corp DE bought a new position in shares of AtriCure in the second quarter worth approximately $24,465,000. Grandeur Peak Global Advisors LLC purchased a new stake in AtriCure in the second quarter valued at approximately $16,435,000. Osterweis Capital Management Inc. bought a new stake in AtriCure during the second quarter valued at approximately $14,028,000. Finally, Marshall Wace LLP lifted its position in AtriCure by 63.4% during the fourth quarter. Marshall Wace LLP now owns 913,453 shares of the medical device company’s stock valued at $36,136,000 after purchasing an additional 354,281 shares during the last quarter. Institutional investors own 99.11% of the company’s stock.

AtriCure Stock Performance

Shares of ATRC stock opened at $51.52 on Friday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The firm has a market cap of $2.62 billion, a price-to-earnings ratio of 245.35 and a beta of 1.26. The stock’s 50-day moving average is $40.10 and its two-hundred day moving average is $32.83. AtriCure, Inc. has a 1 year low of $25.36 and a 1 year high of $53.50.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The business had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period in the previous year, the business posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Analysts predict that AtriCure, Inc. will post 0.29 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Justin Noznesky sold 6,182 shares of the stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $38.80, for a total transaction of $239,861.60. Following the sale, the insider owned 100,219 shares of the company’s stock, valued at $3,888,497.20. This trade represents a 5.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Sven Wehrwein sold 25,000 shares of the stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $37.84, for a total value of $946,000.00. Following the transaction, the director owned 40,518 shares in the company, valued at $1,533,201.12. This trade represents a 38.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 61,379 shares of company stock valued at $2,557,552. Company insiders own 4.00% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on ATRC. Citigroup restated a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. BTIG Research upped their target price on shares of AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a report on Monday, August 24th. Zacks Research lowered shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 24th. Weiss Ratings upgraded shares of AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 19th. Finally, UBS Group dropped their target price on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $52.00.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.